As Costly Lawsuits Hit Opioid Makers, CEOs Collect Bonuses
Companies that sold or distributed opioid medications face huge legal, financial and public relations peril. Critics say shareholders, not CEOs, will pay the price.
[Copyright 2021 NPR]
